RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

Yu Chi Yang, Severin Thompson, David Montgomery, Antonio J López Quiñones, Xing Wei, Benjamin Madej, Aidan Tomlinson, Nataliya Tovbis Shifrin, Alexander McNamara, Ethan Ahler, Ciara Helland, James W. Evans, Laura Lea McDowell, Michael Flagella, John Setser, Stephanie Chang, Zhican Wang, Zhengping Wang, Jun Huang, Steve Ballmer, Shaoling Li, Andreas Buckl, Elena Koltun, Adrian Gill, Jingjing Jiang, Mallika Singh, Jacqueline A Smith